Abbott receives CE Mark for diabetes management system

Abbott has been granted European CE Mark approval for its new FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System, a new diabetes management solution.

This new icon-driven system provides a sleek design, visual glucose trend indicators and insulin logging within a single device to support daily diabetes management and will be available across Europe in the coming weeks.

Its features include a sleek meter design, blood glucose trend indicators that provide visual notifications to patients and an insulin dose feature, which allows a patient's insulin plan to be programmed into the meter.

Heather Mason, senior vice-president for diabetes care at Abbott, said: "The device's advanced design and technology enables the ability to track glucose trends and log insulin, which may help improve the patient's daily diabetes management."

This comes after the firm received CE Mark approval for the Xience Xpedition 48 everolimus-eluting coronary stent system and Architect clinical chemistry haemoglobin A1c test in May 2013.